We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Hemodynamic Effects of Vasopressin in Early Septic Shock Stage

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02053675
Recruitment Status : Completed
First Posted : February 4, 2014
Last Update Posted : February 4, 2014
Information provided by (Responsible Party):

Study Description
Brief Summary:
Vasopressin is a vasopressor used in patients with septic shock. However, its systemic hemodynamic effects and its microcirculation effects are not completely known and understood. This study aimed to evaluate the effect of exogenous vasopressin on sublingual microcirculation using the sidestream dark field technique and to correlate it with its systemic effects. To this prospective interventional study, patients with septic shock were included during the first 48 hours of use of catecholamine vasopressors, admitted to the intensive care unit of a university hospital. Vasopressin was administered at 0.04 U / min for one hour. Systemic hemodynamic measurements were obtained immediately before and 1 hour after vasopressin. In addition, images of sublingual microcirculation were collected through sidestream dark field technology. Further analysis with specific software was done after.

Condition or disease Intervention/treatment
Septic Shock Drug: Vasopressin infusion

  Show Detailed Description

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Hemodynamic Effects of Low Doses of Arginine Vasopressin in Early Septic Shock Stage
Study Start Date : May 2008
Primary Completion Date : April 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Shock
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Vasopressin Drug: Vasopressin infusion

Outcome Measures

Primary Outcome Measures :
  1. The primary objective of this study was to evaluate the effect of vasopressin infusion in microcirculation of septic shock patients [ Time Frame: one hour after vasopressin initiation ]
    Significant changes in microcirculatory parameters - MFI (absolute number), TVD (mm/mm2), PVD (mm/mm2), PPV (%), HI (%)

Secondary Outcome Measures :
  1. The secondary objectives were to evaluate the effects of vasopressin on macrocirculation, and correlate potential microcirculatory effects related to its use, with baseline systemic circulation and microcirculation. [ Time Frame: one hour after vasopressin initiation ]
    Significant changes in HR (bpm), CI (L/min.m2), SI (ml/beat/m2), oxigen delivery (ml/min), lactate (mg/dL), CO2 gradient (mmHg), and correlation between these changes and potential microcirculatory parameters alteration (MFI, TVD, PVD, PPV, HI)

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients over 18 years
  • Septic shock using adrenergic vasopressors for less than 48 hours
  • Arterial catheter and pulmonary artery catheter with semi measurement of cardiac output by thermodilution (Vigilance, Edwards Lifesciences, Irvine, CA, USA) inserted
  • Signed consent declaration

Exclusion Criteria:

  • Acute coronary disease
  • Suspected or confirmed acute mesenteric ischemia
  • Severe hyponatremia (Na + <130 mmol / L)
  • Raynaud's phenomenon
  • Sclerodermia
  • Pregnancy
  • Technical difficulties to capture videomicroscopy with sublingual SDF
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02053675

Hospital São Paulo
São Paulo, São Paulo/SP, Brazil, 04024900
Sponsors and Collaborators
Federal University of São Paulo
Fundação de Amparo à Pesquisa do Estado de São Paulo
More Information

Responsible Party: Flavia Ribeiro Machado, Professor, Federal University of São Paulo
ClinicalTrials.gov Identifier: NCT02053675     History of Changes
Other Study ID Numbers: Vasopress FAPESP 2010/50096-6
First Posted: February 4, 2014    Key Record Dates
Last Update Posted: February 4, 2014
Last Verified: May 2010

Keywords provided by Flavia Ribeiro Machado, Federal University of São Paulo:
septic shock
tissue oxygenation

Additional relevant MeSH terms:
Shock, Septic
Pathologic Processes
Systemic Inflammatory Response Syndrome
Arginine Vasopressin
Vasoconstrictor Agents
Antidiuretic Agents
Natriuretic Agents
Physiological Effects of Drugs